Parabilis Medicines, Inc.

What they do

Parabilis discovers and develops Helicons, stabilized helical peptides engineered to penetrate cells and bind flat intracellular protein surfaces that small molecules and biologics cannot reach. Its lead candidate, zolucatetide, is a direct inhibitor of the β-catenin:TCF interaction and is being evaluated across desmoid tumors, FAP, ACP, hepatocellular carcinoma, colorectal cancer and other Wnt-driven solid tumors. Preclinical programs target ERG and active-state androgen receptor in prostate cancer.

Revenue drivers

• Research collaboration revenue — The company reported $148,000 of revenue in the quarter ended June 30, 2026, versus $0 a year earlier, reflecting early-stage collaboration activity; no product sales exist.
• Regeneron collaboration — A strategic research collaboration with Regeneron to develop Antibody-Helicon Conjugates brought $125M in upfront consideration and equity investment, with potential for up to $2.2B in milestone payments plus tiered royalties.
• Zolucatetide — Lead clinical candidate with no approved product or product revenue; planned Phase 3 registrational trial in desmoid tumors is targeted for the first half of 2027.

Recent performance

Second quarter 2026 revenue was $148,000 versus $0 in the prior-year quarter. The company ended the quarter with $1.1B in cash, cash equivalents and marketable securities following a $770.5M initial public offering and other transactions. Total assets were $1.18B against total liabilities of $127.5M, with shareholder equity of $1.05B and long-term debt of $700,000 as of June 30, 2026. Management said the cash position is expected to fund operations into 2030.

Strategy

Parabilis is advancing zolucatetide as a "pipeline in a product" across multiple Wnt/β-catenin-driven diseases, with desmoid tumors as the lead indication. The company plans to initiate a global registrational Phase 3 trial in desmoid tumors in the first half of 2027 and expects to engage with the FDA in the fourth quarter of 2026. It expects to begin enrollment in a dedicated FAP cohort in the second half of 2026 and to disclose additional FAP data in the first quarter of 2027. The Regeneron collaboration extends the Helicon platform into Antibody-Helicon Conjugates, and the company continues enrolling patients in HCC, CRC and other Wnt-driven solid tumor cohorts.

Risks

• No product revenue — The company is clinical-stage with no approved products and reported only $148,000 of revenue in the most recent quarter, so it depends on financing and collaboration payments to fund operations.
• Clinical and regulatory risk — Zolucatetide's Phase 3 registrational trial in desmoid tumors has not yet started and is planned for the first half of 2027, leaving substantial clinical, regulatory and timeline uncertainty.
• Platform and pipeline concentration — Value is concentrated in the Helicon modality and lead candidate zolucatetide, with the rest of the pipeline preclinical or in early cohorts.
• Collaboration dependence — The Regeneron collaboration provides $125M upfront and potential milestones up to $2.2B, but milestone and royalty payments are contingent on achieving development and commercial objectives.

Outlook

Management expects to present more mature zolucatetide Phase 1/2 desmoid tumor data in the fourth quarter of 2026, including an accepted oral presentation at the ESMO Congress 2026. It plans FDA engagement in the fourth quarter of 2026 to align on the registrational Phase 3 trial, which remains on track to begin in the first half of 2027. FAP enrollment is expected to start in the second half of 2026, with additional FAP data anticipated in the first quarter of 2027 and ACP data in the first half of 2027. The company states its $1.1B cash position should fund operations into 2030.